Compare CCHH & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CCHH | MBAI |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | Malaysia | Israel |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2M | 10.6M |
| IPO Year | N/A | N/A |
| Metric | CCHH | MBAI |
|---|---|---|
| Price | $0.78 | $1.70 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.5M | 51.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $43.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $1.31 |
| 52 Week High | $15.39 | $3.92 |
| Indicator | CCHH | MBAI |
|---|---|---|
| Relative Strength Index (RSI) | 49.24 | 48.03 |
| Support Level | $0.44 | $1.38 |
| Resistance Level | $1.34 | $1.87 |
| Average True Range (ATR) | 0.14 | 0.17 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 35.56 | 45.28 |
CCH Holdings Ltd operates a hotpot restaurant chain in Malaysia, specializing in chicken hotpot and fish head hotpot, mainly under two brand, namely Chicken Claypot House and Zi Wei Yuan, owned by the wholly owned subsidiaries of the Company. The Company conducts its operations through its wholly owned subsidiaries in Malaysia and is engaged as a restaurant operator, licensor and loyalty owner, and general trader. Currently, the Group has developed a restaurant chain including approximately 15 company-owned restaurant outlets, 13 franchised restaurant outlets in Malaysia, and 4 franchised restaurant outlets outside Malaysia.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.